Online inquiry

IVTScrip™ mRNA-Anti-TNFSF13B, LY2127399(Cap 0, 5-Methyl-CTP, 120 nt-poly(A))   (CAT#: GTTS-WQ10399MR)

This product GTTS-WQ10399MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & 5-Methyl-CTP. It ecodes the monoclonal antibody that targets TNFSF13B gene. The antibody can be applied in Autoimmune diseases, Rheumatoid arthritis research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NM_001145645.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 10673
UniProt ID Q9Y275
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-TNFSF13B, LY2127399(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) (GTTS-WQ10399MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ14372MR IVTScrip™ mRNA-Anti-TNF, r-hTBP-1(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA r-hTBP-1
GTTS-WQ13554MR IVTScrip™ mRNA-Anti-GPI-APs, PRX-302(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA PRX-302
GTTS-WQ278MR IVTScrip™ mRNA-Anti-CD37, 177lu-DOTA-HH1(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA 177lu-DOTA-HH1
GTTS-WQ9475MR IVTScrip™ mRNA-Anti-C5AR1, IPH-5401(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA IPH-5401
GTTS-WQ61MR IVTScrip™ mRNA-Anti-H1-0, (131)I-chTNT-1/B(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA (131)I-chTNT-1/B
GTTS-WQ12305MR IVTScrip™ mRNA-Anti-CSF2, MT203(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA MT203
GTTS-WQ1268MR IVTScrip™ mRNA-Anti-EGFR, ABT-414(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA ABT-414
GTTS-WQ12754MR IVTScrip™ mRNA-Anti-TIGIT, OMP-313M32(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA OMP-313M32
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW